EUVIMEDEUVIMED entdecken
Crossref

Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors

Kohei Tsuji iD, Takuya Kobayakawa iD, Peter Bolah, Soshi Nishimura, Tsutomu Murakami, Hirokazu Tamamura iD

ChemBioChem · 2025

DOI: 10.1002/cbic.202500230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Kohei Tsuji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo…. Hauptthemen laut MEDLINE: HIV Fusion Inhibitors, HIV Envelope Protein gp41, HIV-1, Peptides. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science London, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the membrane fusion step is the last chance to block the virus extracellularly, membrane fusion is an important target for anti‐human immunodeficiency virus (HIV) agents. Previously, the dimeric derivatives of C34, which are contained in the HIV‐1 envelope protein gp41 are found, linked by a disulfide bridge or a pegylated linker at its C ‐terminus have more potent anti‐HIV activity than the C34 peptide monomer, and that bivalent inhibitors crosslinking two peptidomimetic small compounds have more potent anti‐HIV activity than the parent small compounds. In the present study, the hybrids of small compounds ( 7 – 9 ) and peptides (SC34 ( 2 ) and SC22EK ( 3 )) are designed as heterodimeric molecules ( 10 – 15 ) to compensate for the drawbacks of the above homodimeric molecules. Some hybrid molecules of small compounds ( 7 – 9 ) and peptide SC22EK ( 3 ) have remarkably higher anti‐HIV activity than peptide SC22EK ( 3 ). Crosslinking small compounds and peptides ( 3 ) is found to be critical for an increase in anti‐HIV activity. Hybrid molecules with small compounds and peptides are useful HIV‐1 fusion inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV Fusion InhibitorsHIV Envelope Protein gp41HIV-1PeptidesSmall Molecule LibrariesHumansPeptide Fragments

Stichwörter der Autor:innen

anti‐HIV‐1 agentsfusion inhibitorshuman immunodeficiency virus type‐1 (HIV‐1)hybrid moleculessmall molecule peptide conjugates

Substanzen

HIV Fusion InhibitorsHIV Envelope Protein gp41PeptidesSmall Molecule Librariespeptide C34Peptide Fragments

Autor:innen und Institutionen

  • Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo, 101-0062, Japan.
  • AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku Tokyo, 162-8640, Japan.

ORCID-Profile: Kohei Tsuji, Takuya Kobayakawa, Hirokazu Tamamura

Förderung

  • Japan Society for the Promotion of Science London
  • Japan Agency for Medical Research and Development

Zitieren

APA

Tsuji, K., Kobayakawa, T., Bolah, P., Nishimura, S., Murakami, T., & Tamamura, H. (2025). Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors. ChemBioChem. https://doi.org/10.1002/cbic.202500230

Vancouver

Tsuji K, Kobayakawa T, Bolah P, Nishimura S, Murakami T, Tamamura H. Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors. ChemBioChem. 2025. doi:10.1002/cbic.202500230

BibTeX
@article{Tsuji2025,
  author = {Tsuji, Kohei and Kobayakawa, Takuya and Bolah, Peter and Nishimura, Soshi and Murakami, Tsutomu and Tamamura, Hirokazu},
  title = {Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202500230}
}
Kostenlos starten →